Despite manufacturing concern, Acacia still expects 1H19 launch for PONV therapy

Despite manufacturing concern, Acacia still expects 1H19 launch for PONV therapy

Submitted by admin on October 8, 2018 - 11:40pm
Source: 
BioCentury
News Tags: 
Acacia Pharma
Barhemsys amisulpride
post-operative nausea and vomiting
PONV
Headline: 
Despite manufacturing concern, Acacia still expects 1H19 launch for PONV therapy
snippet: 

Acacia Pharma Group plc (Euronext:ACPH) said FDA raised a concern related to manufacturing deficiencies in a complete response letter issued Monday for an NDA seeking approval of Barhemsys amisulpride to treat and prevent postoperative nausea and vomiting.

Do Not Allow Advertisers to Use My Personal information